{
    "clinical_study": {
        "@rank": "149788", 
        "arm_group": {
            "arm_group_label": "Experimental Drug TSR-011", 
            "arm_group_type": "Experimental", 
            "description": "Experimental Drug TSR-011"
        }, 
        "brief_summary": {
            "textblock": "TSR-011 is a potent small molecule inhibitor of tyrosine kinases involved in cancer,\n      including:\n\n        1. Anaplastic lymphoma kinase (ALK)\n\n        2. The tropomyosin-related kinases TRKA, TRKB, and TRKC\n\n      This is a sequential, open-label, non-randomized study with dose escalation in Phase 1,\n      followed by expansion at a recommended phase 2 dose."
        }, 
        "brief_title": "A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas", 
        "completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Solid Tumors", 
            "Lymphomas"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Lymphoma", 
                "Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  To be considered eligible to participate in this study, all of the following\n             requirements must be met:\n\n               1. Patients in Phase 1 must have metastatic or locally advanced solid tumors who\n                  have failed to respond to standard therapy\n\n               2. All patients must have confirmation of either ALK positive or TRK positive\n                  status.\n\n               3. Patients in Phase 1 will not be required to have measurable disease. All\n                  patients in Phase 2a will be required to have measurable disease by RECIST.\n\n               4. All patients enrolled in this study must have tumor tissue available.\n\n               5. Patient (male or female) must be \u2265 18 years of age (except where age of majority\n                  is 16 years in a particular country, such as the United Kingdom).\n\n               6. Patient must have performance status \u22642 on the ECOG Performance Scale.\n\n               7. Patient must have an estimated life expectancy of at least 3 months.\n\n               8. Patients must have adequate organ function.\n\n               9. For patients previously treated with myelosuppressive therapy, toxicity must\n                  have recovered to grade 1 or baseline. Non-myelosuppressive therapy patients\n                  must have recovered from all treatment-related toxicities.\n\n              10. Female patients of childbearing potential must have a negative serum pregnancy\n                  test and use adequate birth control for the duration of study\n\n              11. The patient or his or her legal representative must be able to read, understand,\n                  and provide signed informed consent.\n\n              12. Patient is able to understand the study procedures and agrees to participate in\n                  the study by giving written informed consent.\n\n        Exclusion Criteria:\n\n          -  Patients will not be deemed eligible for entry into this study if any of the\n             following criteria are met:\n\n               1. Patient has leukemia.\n\n               2. Patient is a pregnant or lactating female.\n\n               3. Patient has uncontrolled congestive heart failure, angina, or has had a\n                  myocardial infarction in the preceding 3 months.\n\n               4. Ongoing cardiac dysrhythmias\n\n               5. Patients with risk factors for Torsade de point and patients receiving\n                  concomitant medication with QT-prolonging medicines.\n\n               6. Patient has an uncontrolled concurrent medical condition or disease.\n\n               7. Patient has undergone bone marrow or stem cell transplantation in the past 6\n                  months.\n\n               8. Patient has a known hypersensitivity to the components of TSR-011 or the\n                  excipients.\n\n               9. Patient has active or uncontrolled infection.\n\n              10. Patient has a known psychiatric or substance abuse disorder.\n\n              11. Patient has active second primary malignancy.\n\n              12. Patient is observed to have a clinically active central nervous system (CNS)\n                  metastases or carcinomatous meningitis.\n\n              13. Patient has any other severe concurrent disease..\n\n              14. Patient is known to be HIV positive or who has an AIDS-related illness.\n\n              15. Patient has a known history of or active (treated or not) Hepatitis B or C.\n\n              16. Patient has presence of ascites causing significant symptoms.\n\n              17. A patient must stop taking any prescription, over-the-counter, or herbal remedy\n                  known to be an inhibitor or inducer of CYP3A4/5."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 20, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02048488", 
            "org_study_id": "PR-20-5006-C"
        }, 
        "intervention": {
            "arm_group_label": "Experimental Drug TSR-011", 
            "description": "Number of cycles until progression or unacceptable toxicity develops.", 
            "intervention_name": "TSR-011", 
            "intervention_type": "Drug", 
            "other_name": [
                "ALK inhibitor, ALKi", 
                "TRK inhibitor"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "non small cell lung cancer", 
            "NSCLC", 
            "Anaplastic lymphoma kinase", 
            "ALK tyrosine kinase receptor", 
            "ALK+", 
            "TRK+", 
            "ALK inhibitor", 
            "TRK inhibitor", 
            "tropomyosin receptor kinase", 
            "TRKA", 
            "TRKB", 
            "TRKC", 
            "advanced malignancy"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "contact": {
                    "email": "clinicaltrials@ctca-hope.com", 
                    "last_name": "Heather Kieckhefer, RN", 
                    "phone": "(623) 207-3264"
                }, 
                "contact_backup": {
                    "email": "clinicaltrials@ctca-hope.com", 
                    "last_name": "Chari Poteet, RN", 
                    "phone": "623-207-3382"
                }, 
                "facility": {
                    "address": {
                        "city": "Goodyear", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "joschaffer@shc.org", 
                    "last_name": "Joyce Schaffer", 
                    "phone": "480-323-1339"
                }, 
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "yelena.krutikova@cshs.org", 
                    "last_name": "Yelena Krutikova, MD, PhD", 
                    "phone": "310-967-0621"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Tabitha.Hunt@scresearch.net", 
                    "last_name": "Tabitha Hunt, MA, BS", 
                    "phone": "615-524-4091"
                }, 
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "ddavis@evergreen4cure.com", 
                    "last_name": "Diane Davis", 
                    "phone": "509-893-5809"
                }, 
                "facility": {
                    "address": {
                        "city": "Spokane", 
                        "country": "United States", 
                        "state": "Washington"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "enquiries@sarahcannonresearch.co.uk", 
                    "phone": "0044 (0) 20 3219 5200"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas", 
        "overall_contact": {
            "email": "TSR011@tesarobio.com", 
            "last_name": "Clinical Trial Management Group"
        }, 
        "overall_official": {
            "affiliation": "Tesaro, Inc.", 
            "last_name": "Robert Martell, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Institutional Review Board", 
                "United States: Food and Drug Administration", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Incidence of Adverse Events (AEs)", 
            "safety_issue": "Yes", 
            "time_frame": "Approximately 2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02048488"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area Under the Concentration-Time Curve (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Day 1: 0-24 hrs after first dose; pre-dose on days 8 & 15; day 29: 0-24 hours"
            }, 
            {
                "description": "Phase 1, during the dose-escalation phase", 
                "measure": "Maximum Tolerated Dose (MTD)", 
                "safety_issue": "Yes", 
                "time_frame": "28 days after first dose"
            }, 
            {
                "description": "Phase 2", 
                "measure": "Response Rate (RR)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "description": "Phase 1, during the dose escalation phase", 
                "measure": "Dose limiting toxicity (DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "28 days after first dose"
            }, 
            {
                "description": "Phase 2", 
                "measure": "Progression Free Survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }, 
            {
                "description": "Phase 1", 
                "measure": "Recommended Phase 2 Dose (RP2D)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2 years"
            }
        ], 
        "source": "Tesaro, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tesaro, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}